RCUS
Arcus Biosciences IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.84B
P/E Ratio
—
EPS
$-3.29
Beta
0.86
52W High
$26.40
52W Low
$7.06
50-Day MA
$21.44
200-Day MA
$17.12
Dividend Yield
—
Profit Margin
-142.90%
Forward P/E
—
PEG Ratio
—
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Fundamentals
| Revenue (TTM) | $247.00M |
| Gross Profit (TTM) | $-276.00M |
| EBITDA | $-376.00M |
| Operating Margin | -345.40% |
| Return on Equity | -63.30% |
| Return on Assets | -21.10% |
| Revenue/Share (TTM) | $2.30 |
| Book Value | $5.04 |
| Price-to-Book | 4.56 |
| Price-to-Sales (TTM) | 11.49 |
| EV/Revenue | 8.13 |
| EV/EBITDA | 3.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 26.90% |
| Shares Outstanding | $125.35M |
| Float | $88.65M |
| % Insiders | 29.49% |
| % Institutions | 74.45% |
Analyst Ratings
Consensus ($34.20 target)
9
Buy3
HoldData last updated: 4/9/2026